Clinical trials: Botulinum Toxin Type A
Detrusor Muscle Hyperactivity
Neurogenic Detrusor Overactivity Following Spinal Cord Injury or Multiple Sclerosis
The purpose of this study is to determine the efficacy and safety of a single dose of 750 U of Dysport compared to placebo for the improvement in the daily incontinence episode frequency for each administration mode in subjects…
- Trial name
- NCT01357980
- Testing
- Botulinum toxin type A
- Where
- 17 sites in Czechia, France and 3 more
- Volunteers
- 47 people
- Sponsor
- Ipsen
Torticollis
A Prospective, Observational Study of Patients With Cervical Dystonia (Dystonie) Treated With OnabotulinumtoxinA
This is an observational study to assess health-related quality of life in patients with cervical dystonia (dystonie) treated with OnabotulinumtoxinA per routine clinical practice.
- Trial name
- NCT01655862
- Testing
- OnabotulinumtoxinA
- Where
- 8 sites in Canada
- Volunteers
- 62 people
- Sponsor
- Allergan
Lateral Canthal Lines
Safety and Efficacy Study of RT001 to Treat Moderate to Severe Lateral Canthal Lines
The purpose of this study is to evaluate the safety and efficacy of RT001 to treat moderate to severe lateral canthal lines in adults and duration of effect.
- Trial name
- NCT00907387
- Testing
- RT001
- Where
- 9 sites in United States
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- Revance Therapeutics, Inc.
Cervical Dystonia
Study to Evaluate Safety, Efficacy of Botulinum Toxin Type A in Patients With Cervical Dystonia
Study is to investigate the use of the Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS) scale in a cervical dystonia population treated with botulinum toxin type A, and placebo.
- Trial name
- NCT00564681
- Testing
- botulinum toxin type A, botulinum toxin type A Formulation 2, Normal Saline
- Where
- 16 sites in United States, Canada and 14 more
- Volunteers
- 242 people
- Sponsor
- Allergan
Spasticity, Post-Stroke
A Phase III Study to Evaluate the Efficacy and Safety of GSK1358820 in Subjects With Post-stroke Upper Limb Spasticity
Botulinum toxin A (GSK1358820) is a sterile, purified type A botulinum neurotoxin complex. In Japan, 240 units of botulinum toxin A are approved as a maximum dose per administration for upper limb spasticity.
- Trial name
- NCT03261167
- Testing
- Botulinum toxin A (GSK1358820)
- Where
- 38 sites in Japan
- Volunteers
- 124 people
- Sponsor
- GlaxoSmithKline
Anal Fissure
Efficacy Study of Dysport® in the Treatment of Anal Fissure.
To evaluate the effect on healing rates of two different prognostic factors in patients treated with Dysport® for anal fissure: duration of fissure and dose of study drug
- Trial name
- NCT00210444
- Testing
- Botulinum toxin type A
- Where
- 7 sites in Czechia, Poland and 2 more
- Volunteers
- 168 people
- Sponsor
- Ipsen
Plantar Fasciitis
DaxibotulinumtoxinA for Injection for the Treatment of Plantar Fasciitis
This is a randomized, double-blind, placebo-controlled, parallel group, multi-center trial of a single administration of DaxibotulinumtoxinA (DAXI) (high-dose; low-dose) for injection versus placebo for the management of Plantar…
- Trial name
- NCT03825315
- Testing
- DAXI 80 U, DAXI 120 U
- Where
- 20 sites in United States
- Volunteers
- 155 people
- Sponsor
- Revance Therapeutics, Inc.
Glabellar Lines
Evaluate the Efficacy and Safety of INI101 Compared to BOTOX® in Subjects With Moderate to Severe Glabellar Lines.
To evaluate the efficacy and safety of botulinum toxin type A for injection INI101 compared to BOTOX® in subjects with moderate to severe glabellar lines.
- Trial name
- NCT07622004
- Testing
- Botulinum Toxin Type A Injection [INI101], Botulinum Toxin Type A Injection [Botox]
- Where
- South Korea
- Volunteers
- 292 people, healthy volunteers welcome
- Sponsor
- INIBIO Co., Ltd.
Overactive Bladder
Safety and Efficacy Study of Botulinum Toxin Type A for the Treatment of Neurogenic Overactive Bladder
The purpose of this study is to assess the safety and effectiveness of botulinum toxin type A in treating overactive bladder in spinal cord injury or multiple sclerosis patients
- Trial name
- NCT00461292
- Testing
- botulinum toxin Type A (200U), botulinum toxin Type A (300U)
- Where
- 12 sites in United States, Brazil and 10 more
- Volunteers
- 275 people
- Sponsor
- Allergan
Glabellar Lines
Efficacy and Safety of Botulinum Toxin Type A Haemagglutinin Complex Next Generation (BTX-A-HAC NG) in Glabellar Lines
The purpose of the protocol is to demonstrate the safety and the efficacy of a single injection of a new formulation of Clostridium Botulinum toxin type A haemagglutinin complex (BTX A HAC NG) to improve the appearance of…
- Trial name
- NCT02493946
- Testing
- Botulinum toxin type A
- Where
- 24 sites in France, Germany and 1 more
- Volunteers
- 600 people
- Sponsor
- Ipsen
Myofascial Pain Syndromes
Botulinum Toxin Type A (Dysport) Associated With Rehabilitation Treatment in Patients With Primary Myofascial Pain Syndrome
The main purpose of this study is to determine the effectiveness and safety of one dose of botulinum toxin type A (Dysport) associated with rehabilitation treatment on pain control in patients with a type of back pain called…
- Trial name
- NCT00149240
- Testing
- Botulinum toxin type A
- Where
- 4 sites in Spain
- Volunteers
- 24 people
- Sponsor
- Ipsen
COPD
A Study to Evaluate Safety and Efficacy of BOTOX in Adults With Moderate COPD
The aim of this clinical trial to determine the safety and effectiveness of treating the COPD symptoms with subcutaneous BOTOX injections in participants with moderate COPD.
- Trial name
- NCT06003049
- Testing
- OnabotulinumtoxinA
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- RMW Testing